Is Erbitux chemo?
ERBITUX with platinum-based chemotherapy and fluorouracil (CT) was shown to help some people live longer compared to CT alone. Half the patients on ERBITUX with CT were still alive at 10.1 months, compared to 7.4 months with CT alone (median overall survival).
Can Erbitux cure cancer?
Erbitux Offers ‘cure’ Potential To 3 Out Of 4 Advanced Colon Cancer Patients – But Conditions Apply. Researchers have narrowed down the conditions in metastatic colorectal cancer (mCRC) where treatment with the targeted biologic therapy Erbitux (cetuximab) is most likely to succeed.
Do you lose your hair with ERBITUX?
ERBITUX may cause hair changes. Hair changes during EGFR treatment may: Make the eyelashes grow very fast and become very long and bother your eyes. Cause fast growth to eyebrows.
How effective is Erbitux in the first-line treatment of SCCHN?
ERBITUX provides approximately 22% higher exposure relative to the cetuximab product used in the study. These pharmacokinetic data, together with the results of the EXTREME trial and other clinical study data, establish the efficacy of ERBITUX at the recommended dose in the first-line treatment of recurrent locoregional or metastatic SCCHN
What is the role of cetuximab in the treatment of SCCHN/MCRC?
In the meantime, cetuximab, with its highly targeted mechanism of action and synergistic activity with current treatment modalities, is a valuable treatment option in patients with SCCHN and mCRC. Antibodies, Monoclonal / administration & dosage
How is Erbitux used to treat head and neck cancer?
Carefully consider the use of ERBITUX with radiation therapy, or with platinum-based therapy with fluorouracil, in head and neck cancer patients with a history of coronary artery disease, congestive heart failure, or arrhythmias. Closely monitor serum electrolytes, including serum magnesium, potassium, and calcium, during and after ERBITUX therapy.
What are the mortality and morbidity associated with Erbitux?
One patient with no prior history of coronary artery disease died one day after the last dose of ERBITUX. In EXTREME, fatal cardiac disorders and/or sudden death occurred in 3% of the 219 patients with squamous cell carcinoma of the head and neck treated with a cetuximab product in combination with platinum-based therapy and fluorouracil.